IP Library Granted Patent US 7,883,718
Granted Patent B2
US 7,883,718 · App. 12/125,581 · Granted Feb 8, 2011

Methods and devices for the sustained release of multiple drugs

Assignee: The General Hospital Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,883,718
App. No.
12/125,581
Granted
Feb 8, 2011
Kind
B2
Abstract

The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.

Claims (10)

1. A method for delivering a drug to a female mammal, said method comprising the steps of:

(a) preparing a drug delivery device comprising two or more segments, each segment having first and second terminal ends that are each coupled to a terminal end of an adjacent segment, wherein each segment has no membrane and comprises a drug-permeable ethylene-vinyl acetate copolymer, and wherein at least one segment comprises a homogenous mixture of the drug-permeable ethylene-vinyl acetate copolymer and a drug;

(b) positioning in the vaginal tract of the female mammal the drug delivery device of step (a); and

(c) maintaining the drug delivery device in the vaginal tract of the female mammal for a period of time sufficient to deliver an effective amount of the drug to the female mammal, the drug being delivered at a substantially zero-order rate.

2. The method of claim 1 , wherein the drug is a hormone replacement steroid.

3. The method of claim 1 , wherein the drug is a contraceptive agent.

4. The method of claim 1 , wherein the drug is selected from the group consisting of: interferon, anti-angiogenesis factors, growth factors, hormones, enzymes, transferases, hydrolases, lysases, isomerases, proteases, ligases and oxidoreductases, enzyme inhibitors, steroids, anti-cancer drugs and antibiotics.

5. The method of claim 1 , wherein the drug is selected from the group consisting of: growth hormone, polysaccharides, antigens, and antibodies.

6. A method for delivering a drug to a female mammal, comprising:

positioning a substantially ring-shaped drug delivery device in a vaginal tract of a female mammal, the drug delivery device having a plurality of segments, each segment having no outer membrane layer disposed thereon, at least two of the plurality of segments comprising a homogenous mixture of ethylene-vinyl acetate copolymer and a drug, and the at least two segments releasing the drug at a substantially zero-order rate over a prolonged period of time.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2020
From: RON, EYAL S.; CROWLEY, JR., WILLIAM F., M.D.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 053047/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2020
From: LANGER, ROBERT S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053047/0834 →
Continuity (4)
Division 10835414 · Apr 29, 2004
Provisional Application 60466318 · Apr 29, 2003
Provisional Application 60473579 · May 27, 2003
Related Publication 20090274654A1 · Nov 5, 2009